2021 World Conference on Lung Cancer (Posters)-FP07. DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma

FP07. DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Back to course

Video Transcription

Video Summary

The DREMA clinical trial is a phase three randomized clinical trial that aims to explore first-line treatment for advanced pleural mesothelioma using a combination of chemotherapy and immunotherapy. The trial, which is a collaboration between PRECOG, the Thoracic Oncology Group of Australia, and the NHMRC Clinical Trials Group, is based on previous phase two trials that showed promising results. The trial will randomize 480 participants to receive either the experimental arm, which includes ipilimumab, cisplatin, and pemetrexed, or the control arm, which consists of cisplatin or pemetrexed alone. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, objective tumor response rate, adverse events, quality of life, and healthcare resource utilization. The trial is currently ongoing with recruitment in progress.

Asset Subtitle

Anna Nowak

Meta Tag

Speaker Anna Nowak

Topic Mesothelioma, Thymoma and Other Thoracic Malignancies

Keywords

DREMA clinical trial

advanced pleural mesothelioma

chemotherapy

immunotherapy

overall survival